Journal Watch · Cell Systems · 2026

Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger.

A record of this paper's transparent peer review process is included in the supplemental information.

Aliyu L, Wen J, Sunsunwal S et al.Cell Systems3 min readPharma relevance 40/100

DOI: 10.1016/j.cels.2026.101655PMID: 42379170Study type: review / perspective

TL;DR

A record of this paper's transparent peer review process is included in the supplemental information.

Key findings

  • Glycan analysis revealed a substantial reduction in aberrant glycan structures, improved sialylation, and a glycoprofile closely resembling that of plasma-derived HuBChE.
  • These comprehensive modifications to glycosyltransferases and nucleotide sugar donor levels are expected to enhance pharmacokinetics and reduce immunogenicity, positioning rHuBChE as a viable candidate for further preclinical and clinical development against OP poisoning and other medical emergencies.
  • A record of this paper's transparent peer review process is included in the supplemental information.

What they did

HEK293 cells showed the most promising results, prompting extensive glycoengineering targeting over ten glycosylation-related genes to optimize the glycan profile. This involved knocking out genes associated with fucosylation, enhancing sialylation, and reducing glycan branching.

Full abstract (original)

Background: This study assessed three mammalian expression platforms-human embryonic kidney (HEK293), Chinese hamster ovary (CHO), and HepG2 cells-for their ability to produce recombinant human butyrylcholinesterase (rHuBChE), a promising bioscavenger for organophosphate (OP) poisoning treatment. Key challenges remain in producing rHuBChE with a glycosylation profile similar to that of the native human plasma enzyme butyrylcholinesterase (HuBChE), which is critical for its stability and in vivo half-life.

What they did: HEK293 cells showed the most promising results, prompting extensive glycoengineering targeting over ten glycosylation-related genes to optimize the glycan profile. This involved knocking out genes associated with fucosylation, enhancing sialylation, and reducing glycan branching.

Results & conclusions: Glycan analysis revealed a substantial reduction in aberrant glycan structures, improved sialylation, and a glycoprofile closely resembling that of plasma-derived HuBChE. These comprehensive modifications to glycosyltransferases and nucleotide sugar donor levels are expected to enhance pharmacokinetics and reduce immunogenicity, positioning rHuBChE as a viable candidate for further preclinical and clinical development against OP poisoning and other medical emergencies. A record of this paper's transparent peer review process is included in the supplemental information.

Abstract © the authors / Cell Systems (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.cels.2026.101655 · PubMed 42379170.

Why it matters for pharma & biotech

  • Relevant to Biotechnology & Methods teams tracking Cell Systems for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cell Systems study find?

A record of this paper's transparent peer review process is included in the supplemental information.

What type of study is this?

It is a review / perspective, published in Cell Systems in 2026. HEK293 cells showed the most promising results, prompting extensive glycoengineering targeting over ten glycosylation-related genes to optimize the glycan profile.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.cels.2026.101655. PubMed ID: 42379170. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Aliyu L, Wen J, Sunsunwal S et al.. Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger.. Cell Systems (2026). DOI: 10.1016/j.cels.2026.101655.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/glycoform-engineering-of-a-mammalian-platform-to-sculpt-a-humanized-reco-101655/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides